KR102473028B1 - 항-tim-3 항체 및 조성물 - Google Patents
항-tim-3 항체 및 조성물 Download PDFInfo
- Publication number
- KR102473028B1 KR102473028B1 KR1020187032586A KR20187032586A KR102473028B1 KR 102473028 B1 KR102473028 B1 KR 102473028B1 KR 1020187032586 A KR1020187032586 A KR 1020187032586A KR 20187032586 A KR20187032586 A KR 20187032586A KR 102473028 B1 KR102473028 B1 KR 102473028B1
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- antibody
- amino acid
- tim
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321476P | 2016-04-12 | 2016-04-12 | |
| US62/321,476 | 2016-04-12 | ||
| PCT/EP2017/058696 WO2017178493A1 (en) | 2016-04-12 | 2017-04-11 | Anti-tim-3 antibodies and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180133482A KR20180133482A (ko) | 2018-12-14 |
| KR102473028B1 true KR102473028B1 (ko) | 2022-11-30 |
Family
ID=58547516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187032586A Active KR102473028B1 (ko) | 2016-04-12 | 2017-04-11 | 항-tim-3 항체 및 조성물 |
Country Status (35)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20171790A1 (es) | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| UA129904C2 (uk) | 2017-04-05 | 2025-09-10 | Ле Лаборатуар Сервьє | Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку |
| BR112020003362A2 (pt) | 2017-08-28 | 2020-08-18 | Bristol-Myers Squibb Company | antagonistas de tim-3 para o tratamento e diagnóstico de cânceres |
| EP3737700A1 (en) * | 2018-01-12 | 2020-11-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| US12202894B2 (en) | 2018-03-20 | 2025-01-21 | WuXi Biologics Ireland Limited | Anti-TIM-3 antibodies |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| US11807683B2 (en) | 2018-04-12 | 2023-11-07 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding TIM-3 and use thereof |
| AU2019258468B2 (en) * | 2018-04-24 | 2023-06-29 | Ampsource Biopharma Shanghai Inc. | Antibody against TIM-3 and application thereof |
| CN112566936B (zh) | 2018-08-21 | 2024-07-12 | 阿尔伯特爱因斯坦医学院 | 针对人tim-3的单克隆抗体 |
| CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
| EP3897844B1 (en) | 2018-12-19 | 2023-11-15 | Deutsches Krebsforschungszentrum | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| WO2021053490A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| KR102536302B1 (ko) * | 2020-02-25 | 2023-05-26 | 국립암센터 | Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도 |
| US11807688B2 (en) * | 2020-02-28 | 2023-11-07 | Les Laboratoires Servier | Anti-AXL antibodies and compositions |
| CN114057874B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| CN113214396B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| EP4326773A4 (en) | 2021-04-23 | 2025-09-24 | Suzhou Neologics Bioscience Co Ltd | ANTIBODIES TARGETING TIM-3 AND THEIR USES |
| WO2022253805A1 (en) * | 2021-06-01 | 2022-12-08 | Symphogen A/S | Anti-nkg2a antibodies and compositions |
| EP4372006A4 (en) * | 2021-07-16 | 2025-10-08 | Brightpath Biotherapeutics Co Ltd | ANTIBODY OR ANTIBODY DERIVATIVE TO TIM-3 ANTIGEN, AND USE THEREOF |
| CN118043352A (zh) | 2021-09-02 | 2024-05-14 | 德国癌症研究中心公共法律基金会 | 副作用减少的抗cecam6抗体 |
| KR20240050375A (ko) | 2021-09-03 | 2024-04-18 | 온코원 리서치 앤드 디벨롭먼트 게엠베하 | 감소된 응집 가능성과 감소된 소수성을 갖는 개선된 Fc 침묵형 항-oxMIF 항체 |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| KR20250022071A (ko) | 2022-06-02 | 2025-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항체 조성물 및 이의 이용 방법 |
| GB2644480A (en) | 2023-04-24 | 2026-04-15 | King Abdullah Univ Of Science Of Technology | Compositions, systems and methods for multiplex detection of target biomarkers in a sample |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN118373913B (zh) * | 2024-05-08 | 2024-11-01 | 上海百英生物科技股份有限公司 | 一种抗人Tim-3单克隆抗体及其制备方法 |
| CN118165111B (zh) * | 2024-05-15 | 2024-08-13 | 中国人民解放军军事科学院军事医学研究院 | 针对Tim-3的抗体 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010117057A1 (ja) | 2009-04-10 | 2010-10-14 | 協和発酵キリン株式会社 | 抗tim-3抗体を用いた血液腫瘍治療法 |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2015117002A1 (en) * | 2014-01-31 | 2015-08-06 | Novartis Ag | Antibody molecules to tim-3 and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| WO2009097394A2 (en) | 2008-01-29 | 2009-08-06 | The Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| WO2010084999A1 (en) | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| AU2011262758B8 (en) | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CN103936853B (zh) | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
| CA2942245C (en) | 2014-03-12 | 2021-11-02 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
| WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| EP3265486A4 (en) * | 2015-03-06 | 2018-11-14 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3337826A1 (en) | 2015-08-20 | 2018-06-27 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
| WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| JOP20190133A1 (ar) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| UA129904C2 (uk) | 2017-04-05 | 2025-09-10 | Ле Лаборатуар Сервьє | Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку |
| JOP20190222A1 (ar) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
-
2017
- 2017-04-11 PH PH1/2018/502112A patent/PH12018502112B1/en unknown
- 2017-04-11 PL PL17717393T patent/PL3443009T3/pl unknown
- 2017-04-11 AU AU2017251250A patent/AU2017251250B2/en active Active
- 2017-04-11 WO PCT/EP2017/058696 patent/WO2017178493A1/en not_active Ceased
- 2017-04-11 EP EP17717393.7A patent/EP3443009B1/en active Active
- 2017-04-11 LT LTEPPCT/EP2017/058696T patent/LT3443009T/lt unknown
- 2017-04-11 JP JP2018553410A patent/JP7123804B2/ja active Active
- 2017-04-11 PT PT177173937T patent/PT3443009T/pt unknown
- 2017-04-11 US US16/093,024 patent/US11390674B2/en active Active
- 2017-04-11 RS RS20211517A patent/RS62736B1/sr unknown
- 2017-04-11 MX MX2018012076A patent/MX2018012076A/es unknown
- 2017-04-11 SG SG11201808724SA patent/SG11201808724SA/en unknown
- 2017-04-11 NZ NZ746755A patent/NZ746755A/en unknown
- 2017-04-11 MY MYPI2018703580A patent/MY199098A/en unknown
- 2017-04-11 TN TNP/2018/000333A patent/TN2018000333A1/en unknown
- 2017-04-11 MD MDE20190216T patent/MD3443009T2/ro unknown
- 2017-04-11 MA MA44659A patent/MA44659B1/fr unknown
- 2017-04-11 CN CN202310660864.5A patent/CN116693685A/zh active Pending
- 2017-04-11 TW TW106112034A patent/TWI752950B/zh active
- 2017-04-11 HU HUE17717393A patent/HUE056677T2/hu unknown
- 2017-04-11 EA EA201892294A patent/EA039020B1/ru unknown
- 2017-04-11 KR KR1020187032586A patent/KR102473028B1/ko active Active
- 2017-04-11 UA UAA201811058A patent/UA126854C2/uk unknown
- 2017-04-11 IL IL262176A patent/IL262176B2/en unknown
- 2017-04-11 PE PE2018001979A patent/PE20181805A1/es unknown
- 2017-04-11 SG SG10201912937SA patent/SG10201912937SA/en unknown
- 2017-04-11 ES ES17717393T patent/ES2900381T3/es active Active
- 2017-04-11 CN CN201780023412.9A patent/CN109451741B/zh active Active
- 2017-04-11 SI SI201731008T patent/SI3443009T1/sl unknown
- 2017-04-11 CA CA3020647A patent/CA3020647A1/en active Pending
- 2017-04-11 DK DK17717393.7T patent/DK3443009T3/da active
- 2017-04-11 EP EP21194637.1A patent/EP3978531A1/en active Pending
- 2017-04-11 HR HRP20211820TT patent/HRP20211820T1/hr unknown
-
2018
- 2018-09-27 ZA ZA2018/06429A patent/ZA201806429B/en unknown
- 2018-09-28 CO CONC2018/0010458A patent/CO2018010458A2/es unknown
- 2018-10-09 CL CL2018002878A patent/CL2018002878A1/es unknown
- 2018-10-11 SA SA518400222A patent/SA518400222B1/ar unknown
-
2021
- 2021-12-08 CY CY20211101076T patent/CY1125440T1/el unknown
-
2022
- 2022-05-11 US US17/741,967 patent/US12577302B2/en active Active
- 2022-08-10 JP JP2022128330A patent/JP2022172142A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010117057A1 (ja) | 2009-04-10 | 2010-10-14 | 協和発酵キリン株式会社 | 抗tim-3抗体を用いた血液腫瘍治療法 |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| US20130022623A1 (en) | 2011-07-01 | 2013-01-24 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2015117002A1 (en) * | 2014-01-31 | 2015-08-06 | Novartis Ag | Antibody molecules to tim-3 and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102473028B1 (ko) | 항-tim-3 항체 및 조성물 | |
| AU2022204078B2 (en) | Combination therapies targeting PD-1, TIM-3, and LAG-3 | |
| CN108137687B (zh) | 抗ox40抗体及其用途 | |
| RU2755503C2 (ru) | Анти-lag-3 антитела и их композиции | |
| KR102493282B1 (ko) | Tim3에 대한 항체 및 그의 용도 | |
| KR102204937B1 (ko) | 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 | |
| CN109689688B (zh) | 抗icos抗体 | |
| KR20230038311A (ko) | 항-cd73 항체와의 조합 요법 | |
| KR20230017841A (ko) | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 | |
| KR20200108870A (ko) | Tim3에 대한 항체 및 그의 용도 | |
| KR20210068065A (ko) | 안타고니스트 | |
| KR20220160555A (ko) | Cd40에 결합하는 항체 및 이의 용도 | |
| TW202313110A (zh) | 癌症之治療 | |
| KR20230165285A (ko) | Gdf15 신호전달의 치료적 억제제 | |
| RU2795232C2 (ru) | Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3 | |
| HK40082642A (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| HK40082642B (zh) | 靶向pd-1、tim-3及lag-3的组合疗法 | |
| KR20240007760A (ko) | 항-icos 항체의 용도 | |
| HK40003736B (en) | Anti-icos antibodies | |
| NZ789986A (en) | Antibodies against tim3 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20181109 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200401 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211027 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220826 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20221128 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20221128 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |